RECoVERED

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.01501E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $696,170.5
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Amsterdam University Medical Centre
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

As the rapid and unprecedented global spread of COVID-19 is disrupting society worldwide, there is an urgent need to address essential knowledge gaps for optimal clinical and public health management. Important gaps in clinical and pathophysiological knowledge can only be answered through close follow-up of individuals following SARS-CoV-2 infection at a range of disease severities. We will establish a cohort of 300 individuals suffering from different levels of disease severity, ranging from mild illness in community-dwelling individuals to life-threatening illness requiring hospitalization, and follow them at regular intervals for a maximum of 9 months. Using data and biological specimens from this cohort we will (1) identify clinical, virological and/or host factors/response markers predictive of disease progression, (2) determine the kinetics, persistence and protective capacity of SARS-CoV-2-specific antibodies during and following COVID-19 at different levels of disease severity, (3) evaluate characteristics of B and T cell subsets characteristics associated with development of potent neutralizing antibodies, and (4) assess mid- and long term sequelae of COVID-19 and their determinants with respect to morbidity and mortality, pulmonary function, quality of life and psycho-social wellbeing. In addition, a data- and biobank will be established for future, in-depth pathophysiological, immunological, host-genetic and further clinical and epidemiologic studies. Outcomes of this study will help to guide interventions to prevent spread and reduce the severity of illness.